{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:15:32Z","timestamp":1782177332532,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2018.0106"],"award-info":[{"award-number":["2018.0106"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["275469"],"award-info":[{"award-number":["275469"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["237579"],"award-info":[{"award-number":["237579"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["332727"],"award-info":[{"award-number":["332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21-1793Pj"],"award-info":[{"award-number":["21-1793Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["223310"],"award-info":[{"award-number":["223310"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003245","name":"Ministerie van Onderwijs, Cultuur en Wetenschap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["190386"],"award-info":[{"award-number":["190386"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA111412"],"award-info":[{"award-number":["P01 CA111412"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P009500901"],"award-info":[{"award-number":["P009500901"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["834618"],"award-info":[{"award-number":["834618"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2021-073"],"award-info":[{"award-number":["2021-073"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["ICI00024"],"award-info":[{"award-number":["ICI00024"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["024.002.009"],"award-info":[{"award-number":["024.002.009"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","award":["P2020-0038"],"award-info":[{"award-number":["P2020-0038"]}],"id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.actbio.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T12:19:56Z","timestamp":1731154796000},"page":"386-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Interleukin-12 decorated nanosized semiflexible Immunofilaments enable directed targeting and augmented IFN\u03b3 responses of natural killer cells"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-9540","authenticated-orcid":false,"given":"Lea","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Schluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0143-6030","authenticated-orcid":false,"given":"Ren\u00e9","family":"Classens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-5002","authenticated-orcid":false,"given":"Paul K.J.D.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniek","family":"van der Waart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khue G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-6727","authenticated-orcid":false,"given":"David A.","family":"Zaharoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Johan","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Dolstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl G.","family":"Figdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-0040","authenticated-orcid":false,"given":"Ebba","family":"Sohlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-5271","authenticated-orcid":false,"given":"Roel","family":"Hammink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2024.11.012_bib0001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.actbio.2024.11.012_bib0002","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.actbio.2024.11.012_bib0004","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side Effects of Cytokines Approved for Therapy","volume":"37","author":"Baldo","year":"2014","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.actbio.2024.11.012_bib0005","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.actbio.2024.11.012_bib0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunther."},{"issue":"5107","key":"10.1016\/j.actbio.2024.11.012_bib0007","first-page":"547","article-title":"Development of TH1CD4+T cells through IL-12 produced by listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Science (1979)"},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0008","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","article-title":"Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells","volume":"177","author":"Manetti","year":"1993","journal-title":"J. Experim. Med."},{"issue":"7","key":"10.1016\/j.actbio.2024.11.012_bib0009","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/eji.1830260736","article-title":"Interferon-\u03b3-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-\u03b3 production","volume":"26","author":"Micallef","year":"1996","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.actbio.2024.11.012_bib0010","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.actbio.2024.11.012_bib0011","doi-asserted-by":"crossref","first-page":"e46241","DOI":"10.1371\/journal.pone.0046241","article-title":"Differential Effects of IL-12 on Tregs and Non-Treg T Cells: roles of IFN-\u03b3, IL-2 and IL-2R","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS. One"},{"issue":"9","key":"10.1016\/j.actbio.2024.11.012_bib0012","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V87.9.3877.bloodjournal8793877","article-title":"Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10","volume":"87","author":"Sgadari","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.actbio.2024.11.012_bib0013","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.actbio.2024.11.012_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0016","first-page":"3124","article-title":"Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2\u2032-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice","volume":"9","author":"Kozar","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.actbio.2024.11.012_bib0017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/intimm\/7.7.1135","article-title":"Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells","volume":"7","author":"Zou","year":"1995","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0018","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Experim. Med."},{"issue":"7","key":"10.1016\/j.actbio.2024.11.012_bib0019","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12\u2013associated toxicity and interferon-\u03b3 production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-200003000-00003","article-title":"Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID\u2013winn model","volume":"23","author":"Egilmez","year":"2000","journal-title":"Journal of Immunotherapy"},{"issue":"9","key":"10.1016\/j.actbio.2024.11.012_bib0021","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1021\/acsnano.0c03109","article-title":"Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery","volume":"14","author":"Barberio","year":"2020","journal-title":"ACS. Nano"},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0022","doi-asserted-by":"crossref","first-page":"e10453","DOI":"10.1002\/btm2.10453","article-title":"Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors","volume":"8","author":"Barberio","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.actbio.2024.11.012_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0024","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/eji.202048953","article-title":"Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments","volume":"51","author":"Demaria","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2024.11.012_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0026","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2024.11.012_bib0027","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1084\/jem.20111760","article-title":"Proinflammatory cytokine signaling required for the generation of natural killer cell memory","volume":"209","author":"Sun","year":"2012","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0028","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2007-01-068908","article-title":"Colocalization of the IL-12 receptor and Fc\u03b3RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-\u03b3","volume":"111","author":"Kondadasula","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.actbio.2024.11.012_bib0029","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1172\/JCI0215950","article-title":"IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells","volume":"110","author":"Parihar","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.actbio.2024.11.012_bib0030","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.4049\/jimmunol.1000328","article-title":"IL-12 enhances the antitumor actions of trastuzumab via NK Cell IFN-\u03b3 production","volume":"186","author":"Jaime-Ramirez","year":"2011","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.actbio.2024.11.012_bib0031","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.surg.2012.05.035","article-title":"Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell\u2013activating cytokines","volume":"152","author":"Luedke","year":"2012","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0032","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CMR.0000000000000258","article-title":"Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions","volume":"26","author":"Skinner","year":"2016","journal-title":"Melanoma Res."},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1381813","article-title":"Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25","volume":"7","author":"Duggan","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.actbio.2024.11.012_bib0034","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12920-015-0142-9","article-title":"Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12","volume":"8","author":"Campbell","year":"2015","journal-title":"BMC. Med. Genomics"},{"issue":"6","key":"10.1016\/j.actbio.2024.11.012_bib0035","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1039\/c3sc50552a","article-title":"Stiffness versus architecture of single helical polyisocyanopeptides","volume":"4","author":"van Buul","year":"2013","journal-title":"Chem. Sci."},{"issue":"7434","key":"10.1016\/j.actbio.2024.11.012_bib0036","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature11839","article-title":"Responsive biomimetic networks from polyisocyanopeptide hydrogels","volume":"493","author":"Kouwer","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2024.11.012_bib0037","doi-asserted-by":"crossref","unstructured":"Eggermont, L.J., et al., Cytokine-Functionalized synthetic dendritic cells for T cell targeted immunotherapies. Adv. Ther., 2018. 1(6).","DOI":"10.1002\/adtp.201800021"},{"issue":"3","key":"10.1016\/j.actbio.2024.11.012_bib0038","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/acsomega.6b00436","article-title":"Controlling T-cell activation with synthetic dendritic cells using the multivalency effect","volume":"2","author":"Hammink","year":"2017","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.actbio.2024.11.012_bib0039","doi-asserted-by":"crossref","DOI":"10.1039\/c3sc51399h","article-title":"Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy","volume":"4","author":"Mandal","year":"2013","journal-title":"Chem. Sci."},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0040","article-title":"Dictating phenotype, function, and fate of human T cells with co-stimulatory antibodies presented by filamentous immune cell mimics","volume":"5","author":"Schluck","year":"2022","journal-title":"Adv. Ther. (Weinh)"},{"issue":"13","key":"10.1016\/j.actbio.2024.11.012_bib0041","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1021\/acsnano.2c11884","article-title":"Direct in vivo activation of T cells with nanosized immunofilaments inhibits tumor growth and metastasis","volume":"17","author":"Weiss","year":"2023","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2024.11.012_bib0042","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.4c00180","article-title":"Immunofilaments are well tolerated after local or systemic administration in mice","author":"Weiss","year":"2024","journal-title":"ACS. Pharmacol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0043","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1021\/acs.biomac.6b00703","article-title":"Bundle Formation in Biomimetic Hydrogels","volume":"17","author":"Jaspers","year":"2016","journal-title":"Biomacromolecules"},{"issue":"6","key":"10.1016\/j.actbio.2024.11.012_bib0044","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.eurpolymj.2013.01.009","article-title":"Preparation and characterization of non-linear poly(ethylene glycol) analogs from oligo(ethylene glycol) functionalized polyisocyanopeptides","volume":"49","author":"Koepf","year":"2013","journal-title":"Eur. Polym. J."},{"issue":"10","key":"10.1016\/j.actbio.2024.11.012_bib0045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1021\/acs.bioconjchem.7b00398","article-title":"Affinity-Based Purification of Polyisocyanopeptide Bioconjugates","volume":"28","author":"Hammink","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2024.11.012_bib0046","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pep.2014.07.002","article-title":"Efficient production and purification of recombinant human interleukin-12 (IL-12) overexpressed in mammalian cells without affinity tag","volume":"102","author":"Jayanthi","year":"2014","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.actbio.2024.11.012_bib0047","doi-asserted-by":"crossref","unstructured":"Cornelissen, J.J.L.M., et al., Chiral Architectures from Macromolecular Building Blocks. Chem. Rev., 2001. 101(12): p. 4039\u20134070.","DOI":"10.1021\/cr990126i"},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0048","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.celrep.2019.10.058","article-title":"Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity","volume":"29","author":"Pfefferle","year":"2019","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.actbio.2024.11.012_bib0049","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.actbio.2024.11.012_bib0050","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.actbio.2024.11.012_bib0051","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1189\/jlb.0306191","article-title":"Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells","volume":"80","author":"Wendt","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"16","key":"10.1016\/j.actbio.2024.11.012_bib0052","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1073\/pnas.92.16.7307","article-title":"Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes","volume":"92","author":"Bacon","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0053","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4049\/jimmunol.182.2.829","article-title":"IL-12-Dependent inducible expression of the CD94\/NKG2A inhibitory receptor regulates CD94\/NKG2C+ NK cell function1","volume":"182","author":"S\u00e1ez-Border\u00edas","year":"2009","journal-title":"The Journal of Immunology"},{"issue":"2","key":"10.1016\/j.actbio.2024.11.012_bib0054","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.coi.2005.01.007","article-title":"Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer","volume":"17","author":"Ruggeri","year":"2005","journal-title":"Curr. Opin. Immunol."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0055","first-page":"219","article-title":"Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion","author":"Shemesh","year":"2022","journal-title":"J. Experim. Med."},{"issue":"5","key":"10.1016\/j.actbio.2024.11.012_bib0056","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/acs.nanolett.8b01089","article-title":"Activation of human natural killer cells by graphene oxide-templated antibody nanoclusters","volume":"18","author":"Loftus","year":"2018","journal-title":"Nano Lett."},{"issue":"8","key":"10.1016\/j.actbio.2024.11.012_bib0057","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","article-title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell\u2013derived IL-2: a potential new link between adaptive and innate immunity","volume":"101","author":"Fehniger","year":"2003","journal-title":"Blood"},{"issue":"568","key":"10.1016\/j.actbio.2024.11.012_bib0058","doi-asserted-by":"crossref","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.actbio.2024.11.012_bib0059","first-page":"7254","article-title":"Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease","volume":"62","author":"Hill","year":"2002","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.actbio.2024.11.012_bib0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/msy.2001.115839","article-title":"Neoadjuvant therapy with interleukin-12\u2013loaded polylactic acid microspheres reduces local recurrence and distant metastases","volume":"130","author":"Sabel","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.actbio.2024.11.012_bib0061","doi-asserted-by":"crossref","unstructured":"Sabel, M.S., et al., Synergistic effect of intratumoral IL-12 and TNF-\u03b1 microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Surgery, 2007. 142(5): p. 749\u2013760.","DOI":"10.1016\/j.surg.2007.05.008"},{"issue":"6","key":"10.1016\/j.actbio.2024.11.012_bib0062","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-015-1672-x","article-title":"Intravesical chitosan\/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer","volume":"64","author":"Smith","year":"2015","journal-title":"Cancer Immunol. Immunther."},{"issue":"12","key":"10.1016\/j.actbio.2024.11.012_bib0063","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.968001","article-title":"Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis","volume":"3","author":"Vo","year":"2014","journal-title":"Oncoimmunology"},{"issue":"15","key":"10.1016\/j.actbio.2024.11.012_bib0064","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1016\/j.biomaterials.2013.02.031","article-title":"Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity","volume":"34","author":"Yang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2024.11.012_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2024.11.012_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1356666","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity","volume":"15","author":"Stenger","year":"2024","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.actbio.2024.11.012_bib0067","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2009-01-201632","article-title":"Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors","volume":"114","author":"Bryceson","year":"2009","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.actbio.2024.11.012_bib0068","doi-asserted-by":"crossref","first-page":"14651","DOI":"10.1039\/C8NR04038A","article-title":"Natural killer cells\u2019 immune response requires a minimal nanoscale distribution of activating antigens","volume":"10","author":"Keydar","year":"2018","journal-title":"Nanoscale"},{"issue":"27","key":"10.1016\/j.actbio.2024.11.012_bib0069","doi-asserted-by":"crossref","first-page":"eaba8564","DOI":"10.1126\/sciadv.aba8564","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"6","author":"Au","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.actbio.2024.11.012_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.actbio.2024.11.012_bib0071","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells","volume":"56","author":"Bell","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.actbio.2024.11.012_bib0072","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.actbio.2024.11.012_bib0073","article-title":"Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Rep. Med."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124006640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124006640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:25:40Z","timestamp":1778624740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124006640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":73,"alternative-id":["S1742706124006640"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.11.012","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-12 decorated nanosized semiflexible Immunofilaments enable directed targeting and augmented IFN\u03b3 responses of natural killer cells","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}